文献速递肿瘤 PET/CT

18F-FDG PET病灶播散特征可预测弥漫大B细胞淋巴瘤结局

18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome.
PubMed 文献 · J Nucl Med · 2019-06-14

基于LNH073B试验中95例晚期弥漫大B细胞淋巴瘤患者,评估基线18F-FDG PET放射组学播散特征(Dmaxpatient)与代谢肿瘤体积(MTV)的预测价值。高MTV和高Dmaxpatient均为无进展生存(PFS)和总生存(OS)的不良因素;多因素分析中仅Dmaxpatient与PFS显著相关,两者均与OS显著相关。联合MTV(>384 cm3)和Dmaxpatient(>58 cm)可将患者分为3个风险组,进一步改善分期时的风险分层。

要点

  • 高MTV和高Dmaxpatient是DLBCL患者PFS和OS的不良预后因素。
  • 多因素分析中Dmaxpatient与PFS显著相关,MTV和Dmaxpatient均与OS显著相关。
  • 联合MTV(>384 cm3)与Dmaxpatient(>58 cm)可将患者分为3个风险组。

核心结论

  • 将MTV与反映肿瘤负荷播散的参数联合可进一步改善DLBCL患者分期时的风险分层。

研究设计与样本

  • 从LNH073B试验(NCT00498043)中选取具有可审阅基线18F-FDG PET/CT图像的晚期DLBCL患者,计算MTV及包括Dmaxpatient在内的放射组学特征。
  • 采用受试者工作特征分析确定定量变量的最佳截断值,并进行Kaplan-Meier生存分析。
  • 共纳入95例患者,中位年龄46岁,一半接受双周R-CHOP方案,另一半接受R-ACVBP方案,治疗方案对结局无显著影响。

主要发现

  • 中位MTV为375 cm3,中位Dmaxpatient为45 cm,中位随访44个月。
  • 高MTV和Dmaxpatient均为PFS的不良因素(P=0.027和P=0.0003)及OS的不良因素(P=0.0007和P=0.0095)。
  • 多因素分析中仅Dmaxpatient与PFS显著相关(P=0.0014),而MTV和Dmaxpatient均与OS显著相关(P=0.037和P=0.0029)。

关键数值与推荐

  • 联合MTV(>384 cm3)和Dmaxpatient(>58 cm)将患者分为3个风险组,PFS的P=0.0003,OS的P=0.0011。
  • 高危组(2个不良因素,n=18)4年PFS和OS分别为50%和53%。
  • 低危组(无不良因素,n=36)4年PFS和OS分别为94%和97%。
  • 中危组(1个不良因素,n=41)4年PFS和OS分别为73%和88%。

临床怎么用

  • 在DLBCL分期时,可联合基线18F-FDG PET的MTV和Dmaxpatient进行风险分层,识别高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We assessed the predictive value of new radiomic features characterizing lesion dissemination in baseline 18F-FDG PET and tested whether combining them with baseline metabolic tumor volume (MTV) could improve prediction of progression-free survival (PFS) and overall survival (OS) in diffuse large B-cell lymphoma (DLBCL) patients. Methods: From the LNH073B trial (NCT00498043), patients with advanced-stage DLCBL and 18F-FDG PET/CT images available for review were selected. MTV and several radiomic features, including the distance between the 2 lesions that were farthest apart (Dmaxpatient), were calculated. Receiver-operating-characteristic analysis was used to determine the optimal cutoff for quantitative variables, and Kaplan-Meier survival analyses were performed. Results: With a median age of 46 y, 95 patients were enrolled, half of them treated with R-CHOP biweekly (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and the other half with R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone), with no significant impact on outcome. Median MTV and Dmaxpatient were 375 cm3 and 45 cm, respectively. The median follow-up was 44 mo. High MTV and Dmaxpatient were adverse factors for PFS (P = 0.027 and P = 0.0003, respectively) and for OS (P = 0.0007 and P = 0.0095, respectively). In multivariate analysis, only Dmaxpatient was significantly associated with PFS (P = 0.0014) whereas both factors remained significant for OS (P = 0.037 and P = 0.0029, respectively). Combining MTV (>384 cm3) and Dmaxpatient (>58 cm) yielded 3 risk groups for PFS (P = 0.0003) and OS (P = 0.0011): high with 2 adverse factors (4-y PFS and OS of 50% and 53%, respectively, n = 18), low with no adverse factor (94% and 97%, n = 36), and an intermediate category with 1 adverse factor (73% and 88%, n = 41). Conclusion: Combining MTV with a parameter reflecting the tumor burden dissemination further improves DLBCL patient risk stratification at staging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cottereau AS, Nioche C, Dirand AS, et al. 18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome. J Nucl Med. 2019. PMID: 31201248. doi:10.2967/jnumed.119.229450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。